Constellation Pharmaceuticals Appoints Industry Veteran James E. Audia, Ph.D. as Chief Scientific Officer
1/4/2011 8:58:18 AM
(BUSINESS WIRE)--Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the appointment of Dr. James E. Audia as Chief Scientific Officer. Audia joins Constellation following a highly productive career in drug discovery at Eli Lilly and Company.
comments powered by